Protein Therapeutics Market to Surpass USD 566.66 Billion by 2030

Growth of the global protein therapeutics market is attributed to increase in prevalence of chronic diseases, surge in development of protein-based therapies, and various strategies adopted by key players of the market. Moreover, increase in healthcare expenditure and approval of new products are expected to further drive the market growth during the forecast period.

The global protein therapeutics market size was valued at $283.64 Billion in 2020, and is projected to reach $566.66 Billion by 2030, registering a CAGR of 7.1% during the forecast period.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐎𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/60

Therapeutic proteins are an important class of drugs that serve patients in need of novel therapies. They are engineered in laboratories for pharmaceutical use, such as noncovalent binders, proteins that affect covalent bonds (almost all enzymes), and albumin. Therapeutic proteins are extremely effective in vivo and have revolutionized disease treatment. Therapeutic protein products are useful in treatment of a wide range of indications, including cancer, genetic disorders, infectious diseases, and metabolic disorders. These proteins have the potential to reduce morbidity, slow disease progression, and/or replace essential proteins that a patient does not produce endogenously.

Growth of the protein therapeutics market is majorly driven by rise in prevalence of chronic diseases, increase in geriatric population, development of plasma derived therapies, increasing awareness for protein-based therapeutics, and surge in strategic developments among key players of the market.

Key Findings of the Study

By product, the monoclonal antibodies segment was the highest contributor to the protein therapeutics market in 2020.

On the basis of application, the metabolic disorders segment was the highest contributor to the protein therapeutics market in 2020.

Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, and approximately 70% of deaths from cancer occur in low- and middle-income countries. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths is expected to rise to 16.4 million. Thus, rise in prevalence of cancer is anticipated to drive the protein therapeutics market required for drug efficacy and safety.

Moreover, in January 2021, Merck & Co., Inc., and Neoleukin Therapeutics, Inc., announced a clinical trial collaboration and supply agreement with Merck for evaluation of safety and efficacy of Neoleukin's NL-201, a de novo protein, which is designed to mimic the therapeutic activity of natural cytokines IL-2 and IL-15, in combination with Merck's anti-PD-1 therapy Keytruda (pembrolizumab) in an ongoing Phase 1 trial. Thus, such collaborations among key players is expected to further drive the market.

Segment Review:

By PRODUCT:

Monoclonal Antibodies
Insulin
Fusion Protein
Erythropoietin
Interferon
Human Growth Hormone
Follicle Stimulating Hormone

By APPLICATION:

Metabolic Disorders
Immunologic Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others

By Region:

North America (U.S, Canada, Mexico)
Europe (UK, Germany, France, Spain, Italy, Rest of Europe)
Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)

Immediate Delivery Available | Buy this Premium Research Report@ https://www.alliedmarketresearch.com/purchase-enquiry/60

North America accounted for a majority of the global protein therapeutics market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of chronic diseases, adoption of technologically advanced treatments, presence of key players, and rise in healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in R & D activities, increase in disposable income, and improvement in patient awareness toward protein therapeutics.

Key Findings of the Study

By product, the monoclonal antibodies segment was the highest contributor to the protein therapeutics market in 2020.

On the basis of application, the metabolic disorders segment was the highest contributor to the protein therapeutics market in 2020.

Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Key Market Players:

Abbott Laboratories
Amgen Inc.
Baxter International Inc.
Eli Lilly And Company
F. Hoffmann La Roche Ltd
Johnson and Johnson (Janssen Pharmaceuticals)
Merck and Co., Inc.
Novo Nordisk AS
Pfizer Inc.
Sanofi 

Request Customization: https://www.alliedmarketresearch.com/request-for-customization/60

Contact:

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.